Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Efficace, F; Rees, J; Fayers, P; Pusic, A; Taphoorn, M; Greimel, E; Reijneveld, J; Whale, K; Blazeby, J; European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group.
Overcoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry.
Health Qual Life Outcomes. 2014; 12(6):86-86
Doi: 10.1186/1477-7525-12-86
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greimel Elfriede Renate
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Every cancer treatment, irrespective of its clinical effectiveness, has an impact on patients' quality of life (QoL). Even recently developed targeted therapies might have side effects and significantly impact patients' QoL. Thus, understanding the advantages and disadvantages of different treatments from the patient's standpoint has become a must in clinical research and is highly valued by major stakeholders. Thousands of cancer patients are enrolled into randomized controlled trials (RCTs) each year and many complete patient-reported outcome (PRO) instruments to obtain patient-centered information as part of the assessment of the overall effectiveness of the new therapy. Some of these RCTs have generated high quality PRO evidence forming the basis for approval (or support to approval) of drugs by the US Food and Drug Administration. However, a consistent strategy to determine the quality of patient centered evidence presented in RCTs has until recently been lacking. One of the fundamental questions when including PROs in clinical research revolves around methodological robustness and consistency of outcome reporting. Cancer patients, physicians and healthcare system stakeholders need to rely on solid information to make the best possible choice regarding treatment. Therefore generating high-quality findings from PRO assessment in cancer trials is of paramount importance. In an effort to improve quality of PRO assessment and reporting in the near future, the Patient-Reported Outcome Measurements Over Time In ONcology (PROMOTION) Registry was developed. The scope of this Registry is to identify, track, analyse, and store information on all cancer RCTs that have included PROs, and assess the quality of their PRO assessments.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans -
- Neoplasms - psychology
- Patient Outcome Assessment -
- Program Development -
- Randomized Controlled Trials as Topic - methods
- Registries -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Cancer
- Patient-reported outcomes
- Clinical trials
- Quality of life
- Clinical decision-making